414 related articles for article (PubMed ID: 26514968)
21. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol.
Jerling M; Dahl ML; Aberg-Wistedt A; Liljenberg B; Landell NE; Bertilsson L; Sjöqvist F
Clin Pharmacol Ther; 1996 Apr; 59(4):423-8. PubMed ID: 8612387
[TBL] [Abstract][Full Text] [Related]
22. High throughput identification and quantification of 16 antipsychotics and 8 major metabolites in serum using ultra-high performance liquid chromatography-tandem mass spectrometry.
Patteet L; Maudens KE; Sabbe B; Morrens M; De Doncker M; Neels H
Clin Chim Acta; 2014 Feb; 429():51-8. PubMed ID: 24291056
[TBL] [Abstract][Full Text] [Related]
23. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype.
Jaanson P; Marandi T; Kiivet RA; Vasar V; Vään S; Svensson JO; Dahl ML
Psychopharmacology (Berl); 2002 Jun; 162(1):67-73. PubMed ID: 12107620
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of Correlation Between the Pharmacogenetic Profiles of Risperidone Treated Psychiatry Patients with Plasma and Urine Concentration of Risperidone and its Active Moiety 9-OH Risperidone Determined with Optimized Bioanalytical LC Method.
Filipce A; Naumovska Z; Nestorovska AK; Sterjev Z; Brezovska K; Tonic-Ribarska J; Grozdanova A; Suturkova L; Raleva M
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2018 Dec; 39(2-3):97-106. PubMed ID: 30864366
[TBL] [Abstract][Full Text] [Related]
25. Polymorphisms in CYP2D6 have a greater effect on variability of risperidone pharmacokinetics than gender.
Cabaleiro T; Ochoa D; Román M; Moreno I; López-Rodríguez R; Novalbos J; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2015 Feb; 116(2):124-8. PubMed ID: 24975366
[TBL] [Abstract][Full Text] [Related]
26. Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.
Antunes MV; Linden R; Santos TV; Wallemacq P; Haufroid V; Classen JF; Andreolla H; Costa N; Fontanive TO; Rosa DD
Ther Drug Monit; 2012 Aug; 34(4):422-31. PubMed ID: 22777153
[TBL] [Abstract][Full Text] [Related]
27. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone.
Jovanović N; Božina N; Lovrić M; Medved V; Jakovljević M; Peleš AM
Eur J Clin Pharmacol; 2010 Nov; 66(11):1109-17. PubMed ID: 20563569
[TBL] [Abstract][Full Text] [Related]
28. Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype.
Mannheimer B; Haslemo T; Lindh JD; Eliasson E; Molden E
Ther Drug Monit; 2016 Feb; 38(1):127-34. PubMed ID: 26418700
[TBL] [Abstract][Full Text] [Related]
29. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.
Brockmöller J; Kirchheiner J; Schmider J; Walter S; Sachse C; Müller-Oerlinghausen B; Roots I
Clin Pharmacol Ther; 2002 Oct; 72(4):438-52. PubMed ID: 12386646
[TBL] [Abstract][Full Text] [Related]
30. Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?
Jürgens G; Rasmussen HB; Werge T; Dalhoff K; Nordentoft M; Andersen SE
J Clin Psychopharmacol; 2012 Feb; 32(1):100-5. PubMed ID: 22198443
[TBL] [Abstract][Full Text] [Related]
31. Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure.
Kiss Á; Menus Á; Tóth K; Déri M; Sirok D; Gabri E; Belic A; Csukly G; Bitter I; Monostory K
Eur Arch Psychiatry Clin Neurosci; 2020 Feb; 270(1):71-82. PubMed ID: 30604050
[TBL] [Abstract][Full Text] [Related]
32. Impact of genetic variability in CYP2D6, CYP3A5, and ABCB1 on serum concentrations of quetiapine and N-desalkylquetiapine in psychiatric patients.
Bakken GV; Molden E; Hermann M
Ther Drug Monit; 2015 Apr; 37(2):256-61. PubMed ID: 25254417
[TBL] [Abstract][Full Text] [Related]
33. Relation between CYP2D6 Genotype, Phenotype and Therapeutic Drug Concentrations among Nortriptyline and Venlafaxine Users in Old Age Psychiatry.
Berm E; Kok R; Hak E; Wilffert B
Pharmacopsychiatry; 2016 Sep; 49(5):186-190. PubMed ID: 27101231
[No Abstract] [Full Text] [Related]
34. Impact of age and CYP2D6 genotype on exposure of zuclopenthixol in patients using long-acting injectable versus oral formulation-an observational study including 2044 patients.
Tveito M; Smith RL; Molden E; Høiseth G
Eur J Clin Pharmacol; 2021 Feb; 77(2):215-221. PubMed ID: 33000414
[TBL] [Abstract][Full Text] [Related]
35. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.
Leon Jd; Susce MT; Pan RM; Wedlund PJ; Orrego ML; Diaz FJ
Pharmacopsychiatry; 2007 May; 40(3):93-102. PubMed ID: 17541883
[TBL] [Abstract][Full Text] [Related]
36. CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis.
Zhang L; Brown SJ; Shan Y; Lee AM; Allen JD; Eum S; de Leon J; Bishop JR
Pharmacotherapy; 2020 Jul; 40(7):632-647. PubMed ID: 32519344
[TBL] [Abstract][Full Text] [Related]
37. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
[TBL] [Abstract][Full Text] [Related]
38. Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status.
Tveito M; Molden E; Høiseth G; Correll CU; Smith RL
Eur J Clin Pharmacol; 2020 Jan; 76(1):41-49. PubMed ID: 31637453
[TBL] [Abstract][Full Text] [Related]
39. The effect of coadministration of duloxetine on steady-state serum concentration of risperidone and aripiprazole: a study based on therapeutic drug monitoring data.
Hendset M; Molden E; Enoksen TB; Refsum H; Hermann M
Ther Drug Monit; 2010 Dec; 32(6):787-90. PubMed ID: 21068650
[TBL] [Abstract][Full Text] [Related]
40. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.
LLerena A; de la Rubia A; Berecz R; Dorado P
Pharmacopsychiatry; 2004 Mar; 37(2):69-73. PubMed ID: 15048614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]